Since 2018, HitChem has specialized in identifying hit compounds for novel targets. Leveraging proprietary high-throughput virtual screening (HTVS) workflows, high-quality libraries for high-throughput screening (HTS), and AI-assisted rational design, we have helped clients discover over 20 early-stage candidates targeting differentiated mechanisms. Many of these projects have progressed into preclinical and clinical development.
Our capabilities span both dry and wet lab chemistry products and services, along with integrated solutions. In the dry lab, we offer advanced techniques such as CADD, MD simulations, cheminformatics, molecular generative models, and other data-driven methods. In the wet lab, we provide comprehensive chemistry services and custom compound libraries for HTS, including glue libraries for degraders, cyclic peptide libraries for PPI inhibition, highly diverse libraries, SP3-enriched libraries, and covalent libraries.
With a team of over 50 experts—more than 80% of whom hold advanced degrees (Master’s or PhD)—and backgrounds in leading pharmaceutical companies and biotech startups, we have a strong track record of advancing projects from hit identification to clinical development.